Progression of atrophy in Alzheimer's disease and related disorders

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Longitudinal MRI is a powerful tool that allows the assessment of progression of brain changes over multiple imaging time-points and has been increasingly employed in the study of neurodegenerative dementias, particularly Alzheimer's disease (AD). Early studies demonstrated that AD was associated with increased rates of whole brain loss and hippocampal atrophy. A number of sophisticated voxel-level techniques have now been developed that have provided additional information describing regional atrophy over time in the temporal, parietal, and frontal lobes in AD. Studies have also focused on subjects in the prodromal phase of AD in order to describe the earliest changes that are occurring in the brain. Atrophy has been shown to start in the medial temporal lobes and fusiform gyrus at least 3 years before subjects reach a diagnosis of AD, and then spread to the posterior temporal lobes and parietal lobes, and then eventually the frontal lobes. These patterns of atrophy correlate well with the progression of neurofibrillary tangles observed on pathology. Rates of atrophy have also been shown to accelerate over the course of the disease as a subject progresses from cognitively normal to a diagnosis of AD. Similar techniques have also been applied to other neurodegenerative diseases, such as frontotemporal dementia which show higher rates of atrophy and different patterns of progression to those observed in AD. Hence, longitudinal MRI shows promise as a biomarker of disease progression in neurodegenerative disease.

Original languageEnglish (US)
Pages (from-to)339-346
Number of pages8
JournalNeurotoxicity Research
Volume18
Issue number3-4
DOIs
StatePublished - Nov 2010

Fingerprint

Atrophy
Alzheimer Disease
Temporal Lobe
Parietal Lobe
Neurodegenerative diseases
Frontal Lobe
Brain
Neurodegenerative Diseases
Magnetic resonance imaging
Frontotemporal Dementia
Neurofibrillary Tangles
Dementia
Disease Progression
Biomarkers
Pathology
Imaging techniques

Keywords

  • Alzheimer's disease
  • Dementia
  • Longitudinal
  • Magnetic resonance imaging
  • Positron emission tomography
  • Progression
  • Rates

ASJC Scopus subject areas

  • Neuroscience(all)
  • Toxicology

Cite this

Progression of atrophy in Alzheimer's disease and related disorders. / Whitwell, Jennifer Lynn.

In: Neurotoxicity Research, Vol. 18, No. 3-4, 11.2010, p. 339-346.

Research output: Contribution to journalArticle

@article{ae33974157d64a4bbce4a20e19428bd9,
title = "Progression of atrophy in Alzheimer's disease and related disorders",
abstract = "Longitudinal MRI is a powerful tool that allows the assessment of progression of brain changes over multiple imaging time-points and has been increasingly employed in the study of neurodegenerative dementias, particularly Alzheimer's disease (AD). Early studies demonstrated that AD was associated with increased rates of whole brain loss and hippocampal atrophy. A number of sophisticated voxel-level techniques have now been developed that have provided additional information describing regional atrophy over time in the temporal, parietal, and frontal lobes in AD. Studies have also focused on subjects in the prodromal phase of AD in order to describe the earliest changes that are occurring in the brain. Atrophy has been shown to start in the medial temporal lobes and fusiform gyrus at least 3 years before subjects reach a diagnosis of AD, and then spread to the posterior temporal lobes and parietal lobes, and then eventually the frontal lobes. These patterns of atrophy correlate well with the progression of neurofibrillary tangles observed on pathology. Rates of atrophy have also been shown to accelerate over the course of the disease as a subject progresses from cognitively normal to a diagnosis of AD. Similar techniques have also been applied to other neurodegenerative diseases, such as frontotemporal dementia which show higher rates of atrophy and different patterns of progression to those observed in AD. Hence, longitudinal MRI shows promise as a biomarker of disease progression in neurodegenerative disease.",
keywords = "Alzheimer's disease, Dementia, Longitudinal, Magnetic resonance imaging, Positron emission tomography, Progression, Rates",
author = "Whitwell, {Jennifer Lynn}",
year = "2010",
month = "11",
doi = "10.1007/s12640-010-9175-1",
language = "English (US)",
volume = "18",
pages = "339--346",
journal = "Neurotoxicity Research",
issn = "1029-8428",
publisher = "Springer New York",
number = "3-4",

}

TY - JOUR

T1 - Progression of atrophy in Alzheimer's disease and related disorders

AU - Whitwell, Jennifer Lynn

PY - 2010/11

Y1 - 2010/11

N2 - Longitudinal MRI is a powerful tool that allows the assessment of progression of brain changes over multiple imaging time-points and has been increasingly employed in the study of neurodegenerative dementias, particularly Alzheimer's disease (AD). Early studies demonstrated that AD was associated with increased rates of whole brain loss and hippocampal atrophy. A number of sophisticated voxel-level techniques have now been developed that have provided additional information describing regional atrophy over time in the temporal, parietal, and frontal lobes in AD. Studies have also focused on subjects in the prodromal phase of AD in order to describe the earliest changes that are occurring in the brain. Atrophy has been shown to start in the medial temporal lobes and fusiform gyrus at least 3 years before subjects reach a diagnosis of AD, and then spread to the posterior temporal lobes and parietal lobes, and then eventually the frontal lobes. These patterns of atrophy correlate well with the progression of neurofibrillary tangles observed on pathology. Rates of atrophy have also been shown to accelerate over the course of the disease as a subject progresses from cognitively normal to a diagnosis of AD. Similar techniques have also been applied to other neurodegenerative diseases, such as frontotemporal dementia which show higher rates of atrophy and different patterns of progression to those observed in AD. Hence, longitudinal MRI shows promise as a biomarker of disease progression in neurodegenerative disease.

AB - Longitudinal MRI is a powerful tool that allows the assessment of progression of brain changes over multiple imaging time-points and has been increasingly employed in the study of neurodegenerative dementias, particularly Alzheimer's disease (AD). Early studies demonstrated that AD was associated with increased rates of whole brain loss and hippocampal atrophy. A number of sophisticated voxel-level techniques have now been developed that have provided additional information describing regional atrophy over time in the temporal, parietal, and frontal lobes in AD. Studies have also focused on subjects in the prodromal phase of AD in order to describe the earliest changes that are occurring in the brain. Atrophy has been shown to start in the medial temporal lobes and fusiform gyrus at least 3 years before subjects reach a diagnosis of AD, and then spread to the posterior temporal lobes and parietal lobes, and then eventually the frontal lobes. These patterns of atrophy correlate well with the progression of neurofibrillary tangles observed on pathology. Rates of atrophy have also been shown to accelerate over the course of the disease as a subject progresses from cognitively normal to a diagnosis of AD. Similar techniques have also been applied to other neurodegenerative diseases, such as frontotemporal dementia which show higher rates of atrophy and different patterns of progression to those observed in AD. Hence, longitudinal MRI shows promise as a biomarker of disease progression in neurodegenerative disease.

KW - Alzheimer's disease

KW - Dementia

KW - Longitudinal

KW - Magnetic resonance imaging

KW - Positron emission tomography

KW - Progression

KW - Rates

UR - http://www.scopus.com/inward/record.url?scp=78049317979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049317979&partnerID=8YFLogxK

U2 - 10.1007/s12640-010-9175-1

DO - 10.1007/s12640-010-9175-1

M3 - Article

C2 - 20352396

AN - SCOPUS:78049317979

VL - 18

SP - 339

EP - 346

JO - Neurotoxicity Research

JF - Neurotoxicity Research

SN - 1029-8428

IS - 3-4

ER -